Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 09 Jun, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Recent Articles
- China's May Export Growth Surges on AI Wave
- Trump Greeted with Boos at NBA Finals in MSG
- Trump's $100,000 H-1B Visa Fee Declared Unlawful
- OpenAI Files for IPO on Heels of Anthropic
- Bedtime Story: The Scholar Who Entered a Painting
- Sunny Mehta’s Poker Past Highlights Eccentric Path to Devils GM
- First Filipino NBA Champion, LPGA Korean Duo, BYU’s Akina Honored
- China May Exports Pegged for Strong Growth on Front-Loaded Orders, Chip Demand
- China's Global E-Commerce Slides as Iran War Lifts Costs, Dampens Demand
- S. Korea to Seek Priority Supply of Nvidia Vera Rubin GPUs